FACTORS PREDICTING THE RESPONSE OF PATIENTS WITH ADVANCED BREAST-CANCER TO ENDOCRINE (MEGACE) THERAPY
FACTORS PREDICTING THE RESPONSE OF PATIENTS WITH ADVANCED BREAST-CANCER TO ENDOCRINE (MEGACE) THERAPY
复制标题
DOI：
10.1016/0277-5379(89)90259-9
复制
发表时间：
1989-03-01
期刊：
影响因子：
--
通讯作者：
BLAMEY, RW
中科院分区：
文献类型：
--
作者：
ROBERTSON, JFR;WILLIAMS, MR;BLAMEY, RW
我们已经用醋酸甲地孕酮（Megace，百时美施贵宝）治疗了 238 名晚期乳腺癌患者：根据 UICC 标准，221 名患者在 6 个月时可评估缓解情况。 36 名 (16%) 患者有反应，54 名 (25%) 患者病情稳定，131 名 (59%) 患者病情进展。通过对数秩分析计算的从开始 Megace 时起的生存率显示，6 个月时显示缓解的患者与疾病静止的患者之间的生存率没有显着差异。 6 个月内疾病进展的患者的生存期明显短于 6 个月时表现出缓解或疾病静止的患者。 6 个月时对反应进行分类似乎可以识别出患有值得持续时间的静态疾病的患者。原发肿瘤的 ER 状态与开始 Megace 后的生存率显着相关。然而，当 Megace 用作二线激素治疗时，对先前激素治疗的反应或静态疾病的评估比原发肿瘤的 ER 状态更能预测 Megace 的效果。
We have treated 238 patients with advanced breast cancer with megestrol acetate (Megace, Bristol-Myers): 221 were assessable for response at 6 months by UICC criteria. Thirty-six (16%) patients responded, 54 (25%) were static and 131 (59%) progressed. Survival from the time of starting Megace calculated by log-rank analysis showed no significant difference in survival between patients showing response and static disease at 6 months. Patients with progression of disease within 6 months survived significantly shorter than patients who showed response or static disease at 6 months. Categorizing response at 6 months appeared to identify patients who had static disease of worthwhile duration. ER status of the primary tumour correlated significantly with survival from the time of commencing Megace. However, when Megace was used as a second-line hormone therapy the assessment of response or static disease on prior hormone therapy was a better predictor of the effect of Megace than ER status of the primary tumour.